Article
The glutathione transferase Mu null genotype leads to lower 6-MMPR levels in patients treated with azathioprine but not with mercaptopurine.
The pharmacogenomics journal - 1 Jan 2018
Broekman M M T J, Wong D R, Wanten G J A, Roelofs H M, van Marrewijk C J, Klungel O H, Verbeek A L M, Hooymans P M, Guchelaar H-J, Scheffer H, Derijks L J J, Coenen M J H, de Jong D J
Abstract excerpt
The conversion of azathioprine (AZA) to mercaptopurine (MP) is mediated by glutathione transferase Mu1 (GSTM1), alpha1 (GSTA1) and alpha2 (GSTA2). We designed a case-control study with data from the TOPIC trial to explore the effects of genetic variation on steady state 6-methylmercaptopurine ribonucleotide (6-MMPR) and 6-thioguanine nucleotide (6-TGN) metabolite levels. We included 199 patients with inflammatory...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.